For instance, poor responses to immune checkpoint inhibitors are associated with limited gut microbiome diversity and gut inflammation17–22, induced expression of immune checkpoint molecules (including PD-L1, LAG-3, TIM-3)23–27, and immune cell exclusion within the tumor microenvironment28. This evidence concerns the gene CD274 and neoplasm.